Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Melanoma
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Melanoma
    TopAbstracts in Melanoma 11/18/2009 - (DGNews)
    Proton Beam Radiation Therapy for Uveal Melanoma Yields Good Results at a Dose of 56 Gy: Presented at ASTRO - (DGDispatch)
    TopAbstracts in Melanoma 10/21/2009 - (DGNews)
    TopAbstracts in Melanoma 09/23/2009 - (DGNews)
    Study Reveals New Genetic Mutations Involved in Melanoma - (DGNews)

    News archive

     Recent webcasts/CME - Melanoma
    • Moving Beyond Standard Therapy in Malignant Melanoma: Novel Agents and Combinations
    • Adjuvant Interferon Therapy Prolongs Relapse-Free Interval and Survival in Melanoma
    • Rational Vaccine Strategies May Better Harness the Immune System for Anticancer Response in Melanoma
    • Response May Not Be an Appropriate Endpoint for Evaluating Benefit From CTLA-4 Antagonists in Melanoma
    • Emerging Strategies for the Treatment of Metastatic Melanoma: The Role of Monoclonal Antibodies in Targeted Immunotherapy

      Webcasts/CME archive

       Recent cases - Melanoma
        Metastatic Melanoma Presenting as a Thyroid Nodule in a 38-Year-Old Woman
        Diffuse Anorectal Melanoma; Review of the Current Diagnostic and Treatment Aspects Based on a Case Report
        Malignant Melanoma Associated with a Blue Naevus: A Case Report
        Metastatic Malignant Melanoma of the Conjunctiva: A Case Report
        Delayed Malignant Melanoma Recurrence Simulating Primary Ovarian Cancer

        Cases archive
          




        my personal edition > melanoma > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Imiquimod 5% Cream Appears Effective and Safe for Superficial Basal-Cell Carcinoma: Presented at AAD

        By Bruce Sylvester

        WASHINGTON, DC -- February 11, 2004 -- Imiquimod 5% cream (Aldaraź) appears effective for the concurrent treatment of multiple superficial basal-cell carcinoma (sBCCs), researchers reported here on February 7th at the American Academy of Dermatology 62nd Annual Meeting.

        "We saw that, at either 5 or 7 dosings per week, and when used on several sBCCs at one time, there was a high rate of positive outcome," said lead investigator Robin Marks, MB, MPH, Professor of Dermatology, University of Melbourne, St. Vincent's Hospital, Melbourne, Australia. "We had some concern about whether to use it with multiple lesions concurrently, but we found no significant problems…This is good news for our patients, who generally have multiple lesions."

        The study was a 6-week, open-label, multicentre trial. Subjects were assigned to 2 imiquimod treatment groups: 5 times per week for 36 subjects and 7 times per week for 31 subjects. The researchers treated a total of 208 biopsy-confirmed lesions, with a median of 3 per patient.

        Complete response rate was defined as the proportion of subjects with no clinical and histological evidence of sBCC at any of the target tumour sites at 12 weeks treatment. The partial and complete histological response rates were the proportion of subjects who showed histological clearance in at least 50% and 100% of tumours, respectively.

        The investigators reported an overall clearance rate of 77%. For the 5x and 7x groups respectively, the partial histological response rates were 89% and 84%. Complete histological response rates were 47% and 58%, respectively, and the complete response rate was 44% and 55%, respectively.

        "There were some localised site reactions, but no one left the trial for that reason or any other adverse event," stated Professor Marks.

        Imiquimod is approved in the United States to treat genital and anal warts.

        This study was sponsored by 3M Pharmaceuticals.


        [Study title: Imiquimod 5% Cream in the Treatment of Multiple Superficial Basel Cell Carcinoma. Abstract 27]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send